Dupont Capital Management Corp acquired a new position in shares of Zoetis Inc (NYSE:ZTS) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 4,041 shares of the company’s stock, valued at approximately $291,000.

A number of other institutional investors also recently bought and sold shares of ZTS. Bessemer Group Inc. lifted its position in Zoetis by 231,590.8% during the 4th quarter. Bessemer Group Inc. now owns 2,117,654 shares of the company’s stock worth $152,557,000 after acquiring an additional 2,116,740 shares during the period. Acadian Asset Management LLC lifted its holdings in shares of Zoetis by 111.3% in the 4th quarter. Acadian Asset Management LLC now owns 1,709,352 shares of the company’s stock valued at $123,143,000 after buying an additional 900,261 shares during the period. Milestone Resources Group Ltd acquired a new stake in shares of Zoetis in the 4th quarter valued at approximately $40,294,000. Boston Advisors LLC lifted its holdings in shares of Zoetis by 378.9% in the 4th quarter. Boston Advisors LLC now owns 392,944 shares of the company’s stock valued at $28,308,000 after buying an additional 310,893 shares during the period. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Zoetis by 36.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 953,167 shares of the company’s stock valued at $60,763,000 after buying an additional 252,553 shares during the period. 93.73% of the stock is owned by institutional investors.

Several analysts have recently commented on the company. Citigroup raised Zoetis from a “neutral” rating to a “buy” rating and set a $85.00 price target for the company in a report on Thursday, January 4th. Piper Jaffray Companies reissued a “buy” rating and issued a $86.00 price target on shares of Zoetis in a report on Thursday, January 18th. Cantor Fitzgerald reissued a “buy” rating and issued a $75.00 price target on shares of Zoetis in a report on Tuesday, October 24th. BMO Capital Markets reissued a “hold” rating on shares of Zoetis in a report on Monday, January 8th. Finally, Morgan Stanley raised their price target on Zoetis from $61.00 to $70.00 and gave the company an “equal weight” rating in a report on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $73.72.

Zoetis Inc (ZTS) opened at $72.35 on Friday. Zoetis Inc has a one year low of $52.00 and a one year high of $80.13. The firm has a market capitalization of $35,670.00, a P/E ratio of 38.08, a P/E/G ratio of 1.58 and a beta of 1.07. The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, January 19th will be paid a $0.126 dividend. This is an increase from Zoetis’s previous quarterly dividend of $0.11. This represents a $0.50 annualized dividend and a yield of 0.70%. The ex-dividend date is Thursday, January 18th. Zoetis’s dividend payout ratio (DPR) is presently 26.32%.

TRADEMARK VIOLATION WARNING: “Dupont Capital Management Corp Invests $291,000 in Zoetis Inc (ZTS) Stock” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at

Zoetis Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Want to see what other hedge funds are holding ZTS? Visit to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with's FREE daily email newsletter.